Company intelligence / Profile preview

BioROSA Technologies

Belmont, Massachusetts, United Statesbiorosa.com ↗

Ownership: Private
Development stage: Preclinical

Overview

BioROSA Technologies has developed a highly accurate blood-based diagnostic test for early detection of Autism Spectrum Disorder in children as young as 18 months. The test uses proprietary biomarker panels analyzed by machine learning algorithms to provide a risk score for ASD. Clinical validation studies report over 95% sensitivity and over 92% specificity, making it the most accurate solution currently reported in this space. The technology also supports use in therapeutic trials for patient stratification and companion diagnostics.

Therapeutic areas: Psychiatry
Modalities: Diagnostic test (blood-based)Machine learning-based diagnostic tool
Industry: Metabolite Diagnostics

Partnerships

SOSV/IndieBio accelerator partnershipno major pharma partnerships disclosed but used in some therapeutic trials as companion diagnostic tool.

Beyond the preview

Go deeper on BioROSA Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioROSA Technologies.

Explore the full profile